標題
返回
確定
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
Antengene
#
Antengene
About 3 search results
Sort by Date
Business
PR Newswire
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
BOSTON, SINGAPORE and HONG KONG
PR Newswire
2026-06-22 08:30
Antengene
K2 Therapeutics
ATG-106
Business
PR Newswire
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG
PR Newswire
2026-06-10 09:00
Antengene
ATG-201
CD19 x CD3
Business
PR Newswire
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG
PR Newswire
2026-06-03 12:00
ATG-207
Antengene
αCD3-TGF-β